WATERTOWN, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals, a therapeutics company focused on discovering and developing novel gene control therapies, will present a corporate overview at the 33rd Annual J.P. Morgan Healthcare Conference, which takes place January 12 to 15, 2015, at the Westin St. Francis Hotel in San Francisco.
The presentation by Syros CEO Nancy Simonian, MD, is scheduled for Tuesday, January 13, 2015, at 11:00 am Pacific Time in the Elizabethan C room at the Westin St. Francis. The company will present its disruptive gene control platform including recently published research demonstrating in vivo activity of its first-in-class CDK7 inhibitors in cancers driven by transcription factors, as well as identification of novel gene control targets linked to patient subtypes.
About Syros Pharmaceuticals
Syros Pharmaceuticals is a therapeutics company harnessing breakthroughs in gene control to revolutionize the treatment of cancer and other diseases. Syros’ proprietary platform identifies the master switches for disease genes, opening a whole new approach to novel therapeutics and biomarkers. The company’s founders are pioneers in gene control research and translation. Co-founded by Flagship Ventures and ARCH Venture Partners, Syros Pharmaceuticals is located in Watertown, MA. For more information, visit www.syros.com.
Sam Brown Inc.
Mariesa Kemble, 608-850-4745
mariesakemble@sambrown.com
Source: Syros Pharmaceuticals
Released January 7, 2015